Up­dat­ed: A New Jer­sey biotech shuf­fles C-suite, halts pro­mo­tion of yeast in­fec­tion drug and lays off em­ploy­ees

The biotech’s brand­ing tells you to “slay” your vagi­nal yeast in­fec­tion. “Shut that *itch down,” goes the tagline.

Scynex­is is tap­ping in­to its play­book and shut­ting down part of its op­er­a­tions. The Jer­sey City biotech is lay­ing off about 40% of its em­ploy­ees, shak­ing up its ex­ec­u­tive team, nar­row­ing the pipeline and wind­ing down pro­mo­tion­al ac­tiv­i­ties for that ap­proved drug, Brex­afemme, which is on tap for an sN­DA de­ci­sion at the FDA in just six weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER